Immix Biopharma Inc (IMMX)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$8.15-2.40%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Immix Biopharma Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.201
Annual ending 2026-12-31
Revenue	—	12.14M
EPS	—	-0.721
Annual ending 2027-12-31
Revenue	—	26.4M
EPS	—	-0.948

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Control net losses and cash burn	A primary condition in Immix Biopharma Inc's published investment case. The stated target is Net losses not to exceed -$10.1M per quarter.	Under Pressure	Net losses worsen beyond -$10.1M per quarter	Net income: $-11.557M FY2026-Q2; GAAP. Published target: Net losses not to exceed -$10.1M per quarter. The stored target says 2026-Q4; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Source published Aug 7, 2026-11,557,002 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 382085ec-4e91-409c-a105-e65e33551e5f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 6 of last 6 quarters. Operating income worsened from -$4.7M in 2025-Q1 to -$12.5M in 2026-Q2, net income declined similarly, and cash burn remains significant (e.g., -$9.8M cash from operations in 2026-Q1). This indicates limited progress controlling losses and cash burn amid ongoing development. Delivery assessment Oct 24, 2026
Advance NEXICART-2 trial with topline results in Q3 2026	Immix Biopharma is advancing its key NEXICART-2 trial with topline results expected in Q3 2026.	Intact	Topline results not reported by Q3 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters. Management has consistently communicated the plan for NEXICART-2 final readout and BLA submission in mid-2027, with topline results expected in Q3 2026. This priority is delivering as the trial progresses with positive interim clinical results reported in 2026-Q3. Delivery assessment Oct 24, 2026
Begin revenue generation from commercial launch	The company plans a BLA submission and commercial launch thereafter.	Intact	Revenue falls below $45M in FY 2027	Revenue: $0 FY2026-Q2; GAAP. Published target: Revenue >= $45M in FY 2027. Target period is not explicitly aligned with this observation. Source published Aug 7, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 3 of last 3 quarters. Management has consistently communicated the plan for NEXICART-2 final readout and BLA submission in mid-2027, with topline results expected in Q3 2026. This priority is delivering as the trial progresses with positive interim clinical results reported in 2026-Q3. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-0.95

$-0.74 → $-0.95 · observed estimates

FY2027 revenueUnavailable

Unavailable → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-0.74	Unavailable	5 / 4
2026-07-25	$-0.74	Unavailable	5 / 4
2026-07-26	$-0.84	Unavailable	5 / 4
2026-07-27	$-0.84	Unavailable	5 / 4
2026-07-28	$-0.84	Unavailable	5 / 4
2026-07-29	$-0.84	Unavailable	5 / 4
2026-07-30	$-0.84	Unavailable	5 / 4
2026-07-31	$-0.84	$37,610,960	7 / 6
2026-08-01	$-0.84	Unavailable	5 / 4
2026-08-02	$-0.84	$37,610,960	7 / 6
2026-08-03	$-0.84	Unavailable	5 / 4
2026-08-04	$-0.84	$37,610,960	7 / 6
2026-08-05	$-0.84	$37,610,960	7 / 6
2026-08-06	$-0.84	$37,610,960	7 / 6
2026-08-07	$-0.84	Unavailable	5 / 4
2026-08-08	$-0.84	$37,610,960	7 / 6
2026-08-09	$-0.84	$37,610,960	7 / 6
2026-08-10	$-0.84	$37,610,960	7 / 6
2026-08-12	$-0.84	Unavailable	5 / 4
2026-08-13	$-0.84	Unavailable	5 / 4
2026-08-14	$-0.84	Unavailable	5 / 4
2026-08-15	$-0.84	$32,237,963	6 / 5
2026-08-16	$-0.84	$32,237,963	6 / 5
2026-08-17	$-0.84	$32,237,963	6 / 5
2026-08-18	$-0.84	Unavailable	6 / 4
2026-08-19	$-0.84	$32,237,963	6 / 5
2026-08-20	$-0.90	$23,101,468	6 / 5
2026-08-21	$-0.90	$23,101,468	6 / 5
2026-08-22	$-0.90	$23,101,468	6 / 5
2026-08-23	$-0.90	$23,101,468	6 / 5
2026-08-24	$-0.90	$23,101,468	6 / 5
2026-08-25	$-0.90	$23,101,468	6 / 5
2026-08-26	$-0.90	$23,101,468	6 / 5
2026-08-27	$-0.90	$23,101,468	6 / 5
2026-08-28	$-0.90	$23,101,468	6 / 5
2026-08-29	$-0.90	$23,101,468	6 / 5
2026-08-30	$-0.90	$23,101,468	6 / 5
2026-08-31	$-0.90	$23,101,468	6 / 5
2026-09-01	$-0.90	$23,101,468	6 / 5
2026-09-02	$-0.90	$23,101,468	6 / 5
2026-09-03	$-0.90	$23,101,468	6 / 5
2026-09-04	$-0.90	$23,101,468	6 / 5
2026-09-05	$-0.91	$23,101,468	6 / 5
2026-09-06	$-0.91	$23,101,468	6 / 5
2026-09-07	$-0.91	$23,101,468	6 / 5
2026-09-08	$-0.91	$23,101,468	6 / 5
2026-09-09	$-0.91	$23,101,468	6 / 5
2026-09-10	$-0.91	$23,101,468	6 / 5
2026-09-11	$-0.91	$23,101,468	6 / 5
2026-09-12	$-0.91	$23,101,468	6 / 5
2026-09-13	$-0.91	$23,101,468	6 / 5
2026-09-14	$-0.91	$23,101,468	6 / 5
2026-09-15	$-0.91	$23,101,468	6 / 5
2026-09-16	$-0.86	$23,101,468	6 / 5
2026-09-17	$-0.86	$23,101,468	6 / 5
2026-09-18	$-0.86	$23,101,468	6 / 5
2026-09-19	$-0.86	$23,101,468	6 / 5
2026-09-20	$-0.86	Unavailable	6 / 4
2026-09-21	$-0.86	Unavailable	6 / 4
2026-09-22	$-0.86	Unavailable	6 / 4
2026-09-23	$-0.86	Unavailable	6 / 4
2026-09-24	$-0.86	Unavailable	6 / 4
2026-09-25	$-0.86	Unavailable	6 / 4
2026-09-26	$-0.86	Unavailable	6 / 4
2026-09-27	$-0.86	Unavailable	6 / 4
2026-09-28	$-0.86	Unavailable	6 / 4
2026-09-29	$-0.86	Unavailable	6 / 4
2026-09-30	$-0.86	Unavailable	6 / 4
2026-10-01	$-0.85	Unavailable	6 / 4
2026-10-02	$-0.85	Unavailable	6 / 4
2026-10-03	$-0.85	Unavailable	6 / 4
2026-10-04	$-0.85	Unavailable	6 / 4
2026-10-05	$-0.85	Unavailable	6 / 4
2026-10-06	$-0.85	Unavailable	6 / 4
2026-10-07	$-0.85	Unavailable	6 / 4
2026-10-08	$-0.85	Unavailable	6 / 4
2026-10-09	$-0.85	Unavailable	6 / 4
2026-10-10	$-0.85	Unavailable	6 / 4
2026-10-11	$-0.85	Unavailable	6 / 4
2026-10-12	$-0.85	Unavailable	6 / 4
2026-10-13	$-0.85	Unavailable	6 / 4
2026-10-14	$-0.85	Unavailable	6 / 4
2026-10-15	$-0.85	Unavailable	6 / 4
2026-10-16	$-0.85	Unavailable	6 / 4
2026-10-17	$-0.85	Unavailable	6 / 4
2026-10-18	$-0.85	Unavailable	6 / 4
2026-10-19	$-0.85	Unavailable	6 / 4
2026-10-20	$-0.85	Unavailable	6 / 4
2026-10-21	$-0.95	Unavailable	6 / 4
2026-10-22	$-0.95	Unavailable	6 / 4
2026-10-23	$-0.95	Unavailable	6 / 4
2026-10-24	$-0.95	Unavailable	6 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	4	0	0
2026-06-01	6	0	0
2026-07-01	7	0	0
2026-08-01	7	0	0
2026-09-01	7	0	0
2026-10-01	7	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

Morgan StanleyOct 20 · prior Aug 11

$19.00 → $20.00+5.3%

$0$11.00$22.00

1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Control net losses and cash burnPublished status: Under Pressure
Advance NEXICART-2 trial with topline results in Q3 2026Direct metric needs a verified mapping
Begin revenue generation from commercial launchRevenue: $0

Next proof point

Nov 6, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.0%Typical daily move · historical

Downside history

-44.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Immix Biopharma Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, not a proven earnings compounder. Its multi-year thesis is in a watch state, with low overall evidence confidence and a high-risk profile.

What's priced into Immix Biopharma Inc

The snapshot gives no valuation level or expectations estimate, so it does not support a view on whether IMMX is cheap or expensive versus peers or what the market already assumes. No priced-in fragility gates have fired, but that does not resolve the uncertainty around the business.

What the fundamentals likely do

Near term, trial progress offers some support: management reported positive interim NEXICART-2 results in Q3 2026 and expects topline results in Q3 2026, followed by a planned mid-2027 final readout and BLA submission. Loss control remains weak, and the $125 million stock offering supports development and working capital through mid-2028 while adding shares; the next results also carry elevated miss risk.

What Immix Biopharma Inc hinges on

The multi-year thesis hinges on NEXICART-2 progress and whether the planned readout and submission milestones are achieved. Near term, a guidance cut or continued deterioration in jobs data could add pressure, while strong results and guidance from sector peers could support the healthcare backdrop.